Longevity Industry 1.0 - Defining the Biggest and Most Complex Industry in Human History

Quotes and Advance Reviews 8
Preface by Margaretta Colangelo 11
Preface by Dmitry Kaminskiy 14
Facts vs. Fiction 19
PART I - Longevity Mega-Complexity: Challenges, Issues, Opportunities 25
1. The Biggest and Most Complex Industry in Human History 26
2. Formulating the Longevity Industry Framework 40
3. From BioTech Stagnation to Longevity: Forecasting on the Future of Longevity Biomedicine 56
4. Longevity Investing 1.0: Disproportions in the Current Longevity Investment Landscape 64
5. Longevity Investing 2.0: Why Traditional BioTech Analytics Fails Against the Longevity Industry’s Extreme Complexity 71
6. Longevity.Capital: Specialized Hybrid Investment Fund for Longevity Industry, De-Risking and Diversification 81
PART II - Longevity Policy and Governance 91
7. The Rise of Longevity Technocracies and MegaHubs: Governance and Policy as the Next Great Longevity Frontier (Contributor: Eric Kihlstrom) 92
8. Longevity Progressive and Regressive Nations: Israel, Singapore and the USA 118
9. The Swiss Longevity Valley: How Switzerland May Become a Global Longevity Financial Industry MegaHub by 2025 (Contributor: Stefan Hascoet) 131
10. The Longevity Leadership Role of the UK: The Emergence of Longevity-Focused Parliamentary Groups and Government Bodies (Contributor: Eric Kihlstrom) 148
11. California - Longevity Hype in Silicon Valley: Will the Traditional Approach to BioTech Investment Lead to a Longevity Boom, Bubble or Bust? (Contributor: Kate Batz) 166
12. The Future of Longevity Governance: How Longevity Will Become a Major Priority Item for the National Agendas
of Progressive Countries by 2025 176
PART III - Longevity Financial Industry 178
13. The Longevity Financial Industry and Novel Financial System 179
14. Major Longevity Financial Industry Trends, Predictions and Insights 196
15. Longevity FinTech (Contributor: Sergey Balasanyan) 220
16. Longevity Finance and the Shift from FinTech 1.0 to FinTech 2.0 235
17. FinTech 2.0 and the Rise of Longevity Banks: Where Healthspan Meets Wealthspan 239
PART IV - Longevity Industry (Science, Technology & Biomedicine) 257
18. The Birth and Rise of Geroscience (The Science of Longevity) 258
19. Most Developed Domains of Longevity R&D and Top Longevity Scientists 264
20. The Current State of Longevity Clinical (Human) Trials 281
21. Precision Medicine and the Patient as CEO (Contributor: Robin Farmanfarmaian) 287
22. AI for Longevity and Precision Health (Contributor: Richard Siow) 299
23. Longevity FemTech (Contributor: Robin Farmanfarmaian) 309
24. Biomarkers of Longevity 2.0: The Shift Toward Actionable, AI-Empowered Biomarkers of Aging, Health and Longevity (Contributor: Franco Cortese) 316
25. The Crucial and Fundamental Role of AI in Longevity R&D and Practical Implementation 331
26. What if Geroscience Fails? - Pragmatic Optimism in the Longevity Industry and Defining Hype vs. Reality 346
Longevity Industry 2.0 Summary - DeepTech Engineering The Accelerated Trajectory of Human Longevity: The Blueprint and Pathway from 1.0 to 2.0 356
PART V - Longevity Industry Navigator 359
1. Longevity Industry in UK Landscape Overview 2018 360
2. Longevity Industry in Singapore Landscape Overview 2019 360
3. Longevity Industry in Israel Landscape Overview 2019 361
4. FemTech Healthcare Landscape Overview 2019 362
5. Longevity Industry in California Landscape Overview 2019 363
6. Top-100 Longevity Leaders 364
7. Top-100 Journalists Covering Advanced Biomedicine and Longevity 365
8. Top-50 Women Longevity Leaders 366
9. Top-30 Longevity Conferences 367
10. Advancing Financial Industry Longevity / AgeTech / WealthTech 368
11. Longevity Industry in Switzerland Landscape Overview 2019 369
12. Top-100 Supercentenarians Landscape Overview: 100 Longest-Lived, 100 Currently Living, 25 Socially and Professionally Active 370
13. 1000 Longevity Leaders IT-Platform 371
About Deep Knowledge Group 347
About the Authors 381
About the Contributors 383